marked.bio

Company

CARsgen Therapeutics

3 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

satricabtagene autoleucel 3apatinib 1

Trials

3 of 4 trials shown

  1. Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

    Active, not recruiting Phase 1/2 CARsgen Therapeutics Started 2020Primary completion 2025-06 NCT04404595

    satricabtagene autoleucel

    Must have CLDN18.2-positive tumor expression as determined by the CLDN18.2 IHC assay;

    Claudin 18.2 expressionGastric Cancer, Pancreatic Cancer

  2. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

    Active, not recruiting Phase 1/2 CARsgen Therapeutics Started 2020Primary completion 2024-10 NCT04581473

    satricabtagene autoleucelpaclitaxelirinotecanapatinib

    Phase Ib：Tumor tissue samples were positive for CLDN18.2 IHC staining； Phase II：Tumor tissue samples were positive for CLDN18.2 IHC staining and H…

    Claudin 18.2 expressionGastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma

  3. A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

    Recruiting Phase 1 CARsgen Therapeutics Started 2023Primary completion 2026-12 NCT05911217

    satricabtagene autoleucel

    Immunohistochemistry (IHC) staining of subject's tumor tissue sample is CLDN18.2-positive;

    Claudin 18.2 expressionPancreatic Cancer